Alps Advisors Inc. Sells 18,052 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Alps Advisors Inc. cut its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPSGet Rating) by 41.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,216 shares of the company’s stock after selling 18,052 shares during the period. Alps Advisors Inc. owned approximately 0.06% of COMPASS Pathways worth $273,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CMPS. Banque Cantonale Vaudoise raised its stake in shares of COMPASS Pathways by 191.3% in the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the company’s stock valued at $32,000 after purchasing an additional 1,970 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of COMPASS Pathways in the 1st quarter valued at about $39,000. Quantbot Technologies LP raised its stake in shares of COMPASS Pathways by 156.8% in the 1st quarter. Quantbot Technologies LP now owns 3,338 shares of the company’s stock valued at $43,000 after purchasing an additional 2,038 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of COMPASS Pathways by 304.0% in the 2nd quarter. Exchange Traded Concepts LLC now owns 6,480 shares of the company’s stock valued at $70,000 after purchasing an additional 4,876 shares during the period. Finally, Commonwealth Equity Services LLC raised its stake in shares of COMPASS Pathways by 17.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 11,956 shares of the company’s stock valued at $129,000 after purchasing an additional 1,797 shares during the period. 16.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CMPS has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Tuesday, October 18th. Oppenheimer lowered their target price on COMPASS Pathways from $65.00 to $55.00 in a research report on Thursday, October 13th. Loop Capital began coverage on COMPASS Pathways in a research report on Tuesday, November 1st. They issued a “buy” rating and a $34.00 target price on the stock. Cantor Fitzgerald lowered their target price on COMPASS Pathways from $58.00 to $35.00 in a research report on Friday, August 5th. Finally, Canaccord Genuity Group lowered their target price on COMPASS Pathways from $78.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 13th.

COMPASS Pathways Stock Up 4.8 %

Shares of NASDAQ CMPS opened at $10.48 on Thursday. The business’s 50 day moving average price is $10.89 and its two-hundred day moving average price is $12.12. The company has a market cap of $446.21 million, a PE ratio of -5.22 and a beta of 2.32. COMPASS Pathways plc has a twelve month low of $6.54 and a twelve month high of $34.79.

About COMPASS Pathways

(Get Rating)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.

Read More

Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for COMPASS Pathways plc (NASDAQ:CMPSGet Rating).

Institutional Ownership by Quarter for COMPASS Pathways (NASDAQ:CMPS)

Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.